GERON CORP (GERN)
GERON CORP (GERN) from its SEC filings: 2023 revenue $237,000 (-60% vs the year before), net margin -77691%, free cash flow -$168.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2023) | $237,000 |
| Revenue growth | -60% |
| Net income | -$184.1 million |
| Net margin | -77690.7% |
| Free cash flow | -$168.6 million |
| Diluted EPS | $-0.32 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +17% |
| Cash | $62.6 million |
| Long-term debt | $120.1 million |
| Share count, 1 year | +1% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.